RT Journal Article
SR Electronic
T1 PROactive: In Prior MI Patients Pioglitazone Lowers Risks
JF MD Conference Express
YR 2005
FD SAGE Publications
VO 5
IS 1
SP 16
OP 16
DO 10.1177/155989770501007
UL http://mdc.sagepub.com/content/5/1/16.abstract
AB PROactive, a prospective, multicenter, randomized, doubleblind placebo-controlled parallel-group trial, compared up to 45 mg/day of pioglitazone (PGZ) on top of other medication (optimal treatment of diabetes, dyslipidemia and hypertension) to placebo in 5,238 patients with type 2 diabetes and macrovascular disease. The PROactive study objective was to see if the glucose-lowering agent, already known to have beneficial effects on cardiovascular disease risk factors such as HDL cholesterol, triglycerides, LDL particle size and inflammatory mediators, would reduce total mortality and macrovascular morbidity in these high-risk patients.